BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26273374)

  • 1. Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis.
    Ma Y; Fan M; Dai L; Kang X; Liu Y; Sun Y; Xiong H; Liang Z; Yan W; Chen K
    Thorac Cancer; 2015 May; 6(3):288-95. PubMed ID: 26273374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p40 (ΔNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a review and comparative analysis.
    Vogt AP; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2014 May; 42(5):453-8. PubMed ID: 24166777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double staining: diagnostic utility in non-small cell lung carcinoma in the era of tissue conservation.
    Hosny Mohammed K; Ewaz A; Cohen C; Siddiqui MT
    J Am Soc Cytopathol; 2017; 6(4):170-175. PubMed ID: 31043270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined double CK5/P63 stain: useful adjunct test for diagnosing pulmonary squamous cell carcinoma.
    Fatima N; Cohen C; Lawson D; Siddiqui MT
    Diagn Cytopathol; 2012 Nov; 40(11):943-8. PubMed ID: 21472873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer.
    Kriegsmann K; Cremer M; Zgorzelski C; Harms A; Muley T; Winter H; Kazdal D; Warth A; Kriegsmann M
    Pathology; 2019 Apr; 51(3):240-245. PubMed ID: 30798982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens.
    Khayyata S; Yun S; Pasha T; Jian B; McGrath C; Yu G; Gupta P; Baloch Z
    Diagn Cytopathol; 2009 Mar; 37(3):178-83. PubMed ID: 19170169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation.
    Righi L; Graziano P; Fornari A; Rossi G; Barbareschi M; Cavazza A; Pelosi G; Scagliotti GV; Papotti M
    Cancer; 2011 Aug; 117(15):3416-23. PubMed ID: 21246522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases.
    Gurda GT; Zhang L; Wang Y; Chen L; Geddes S; Cho WC; Askin F; Gabrielson E; Li QK
    Clin Transl Med; 2015; 4():16. PubMed ID: 25977750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations.
    Lilo MT; Allison D; Wang Y; Ao M; Gabrielson E; Geddes S; Zhang H; Askin F; Li QK
    J Am Soc Cytopathol; 2016; 5(3):123-132. PubMed ID: 27699149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma.
    Tran L; Mattsson JS; Nodin B; Jönsson P; Planck M; Jirström K; Botling J; Micke P; Brunnström H
    Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):648-659. PubMed ID: 26447895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas.
    Noh S; Shim H
    Lung Cancer; 2012 Apr; 76(1):51-5. PubMed ID: 21978426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
    Vincenten JP; Smit EF; Grünberg K; Postmus PE; Snijders PJ; Witte BI; Heideman DA; Thunnissen E
    Lung Cancer; 2015 Jul; 89(1):19-26. PubMed ID: 25982011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of p40 (ΔNp63) with p63 and cytokeratin 5/6 immunohistochemistry in non-small cell lung carcinoma fine-needle aspiration biopsy.
    Collins BT; Wang JF; Bernadt CT
    Acta Cytol; 2013; 57(6):619-24. PubMed ID: 24107322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of TTF-1, NapsinA, P63, CK5/6 in Lung Cancer and Its Diagnostic Values for Histological Classification].
    Yu H; Li L; Liu D; Li WM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 May; 48(3):336-341. PubMed ID: 28616902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal positivity of immunohistochemical markers for pulmonary squamous cell carcinoma in primary pulmonary choriocarcinoma: A histopathological study.
    Matsukuma S; Obara K; Utsumi Y; Miyai K; Takeo H; Oshika Y; Sensaki K
    Oncol Lett; 2018 Dec; 16(6):7256-7263. PubMed ID: 30546464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
    Mukhopadhyay S; Katzenstein AL
    Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.
    Tsuta K; Tanabe Y; Yoshida A; Takahashi F; Maeshima AM; Asamura H; Tsuda H
    J Thorac Oncol; 2011 Jul; 6(7):1190-9. PubMed ID: 21623236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients.
    Stefansson IM; Salvesen HB; Akslen LA
    Int J Cancer; 2006 Mar; 118(5):1227-33. PubMed ID: 16152605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of p63, p40 and CK5/6 in small cell lung cancer].
    Zhang L; Hou L; Xie H; Dong Z; Wu W; Kong J; Chen G; Wu C
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):644-7. PubMed ID: 26705280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.